Teva rides growth momentum through Q2, boosts '24 sales outlook

Teva and its long-term investors have been through much disappointment over the last decade, but 2024 is bringing optimism for the Israeli drugmaker.

During the second quarter of the year, Teva grew sales 11% in local currency terms to $4.2 billion. The performance comes after the company reported a 5% revenue increase during the first quarter.